drugset / Trial / NCT00890240
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (process by which JNJ-31001074 is absorbed, distributed, metabolized, and eliminated by the body) after a single dose of JNJ-31001074. Up to three dose strengths will be tested in patients 6-11 years old with attention deficit hyperactivity disorder (ADHD).
Timeline
- Start
- 2009-05
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bavisant | Small molecule | 0.015 mg/kg | Oral |
| Subject | bavisant | Small molecule | 0.045 mg/kg | Oral |
| Subject | bavisant | Small molecule | 0.15 mg/kg | Oral |